Increasing Cancer And Cardiovascular Disease Prevalence Fuels Demand For Radiopharmaceuticals Is Supporting Development Across The Radiopharmaceuticals Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Is The Radiopharmaceuticals Market’s Market Value Anticipated To Evolve From 2026 To 2030?

The radiopharmaceuticals market has seen rapid expansion in recent years. It is projected to grow from $7.3 billion in 2025 to $8.25 billion in 2026, at a compound annual growth rate (CAGR) of 13.0%. This historical growth can be attributed to various factors including the adoption of nuclear imaging technologies, an increase in cancer diagnosis rates, the availability of radioisotopes, the expansion of hospital-based nuclear medicine, and regulatory approvals for diagnostic agents.

The radiopharmaceuticals market is projected to expand significantly in the coming years. It is set to reach $13.68 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 13.5%. This expansion during the forecast period is primarily driven by advancements in precision oncology, the increasing need for targeted radiotherapies, the proliferation of diagnostic imaging centers, investments in cyclotron infrastructure, and innovations in isotope production technology. Notable trends anticipated during this period include the growing application of radiopharmaceuticals in oncology, the rise of theranostics, the broadening scope of PET and SPECT imaging, the continuous development of targeted radiotherapies, and enhancements in nuclear medicine infrastructure.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp

What Influential Factors Are Boosting The Radiopharmaceuticals Market Demand?

The escalating occurrence of cancer and cardiovascular diseases is anticipated to propel the demand for the radiopharmaceuticals market. Radiopharmaceuticals are emerging as a secure and potent therapeutic alternative to conventional medicines. Due to benefits such as targeted therapy, radiopharmaceuticals offer radiologists a distinct advantage in treating cancer and cardiovascular diseases. Cancer is globally recognized as the second leading cause of death, contributing to approximately 1 in 6 deaths worldwide. For instance, in April 2024, the International Agency for Research on Cancer (IARC), a specialized agency based in France, reported that in 2022, nearly 20 million new cancer cases and 9.7 million cancer-related deaths occurred globally. By 2040, these figures are projected to climb to 29.9 million new cases and 15.3 million deaths annually. Thus, the increasing instances of cancer and cardiovascular diseases are expected to significantly boost the demand for radiopharmaceuticals for their treatment.

What Segment Types Are Included In The Radiopharmaceuticals Market Analysis?

The radiopharmaceuticals market covered in this report is segmented –

1) By Type: Diagnostic, Therapeutic

2) By Application: Oncology, Cardiology, Gastroenterology, Neuroendocrinology, Musculoskeletal, Respiratory, Nephrology, Other Applications

3) By End User: Hospitals And Ambulatory Surgical Centers, Diagnostic Centers, Cancer Research Institutes

Subsegments:

1) By Diagnostic: Positron Emission Tomography (PET) Radiopharmaceuticals, Single Photon Emission Computed Tomography (SPECT) Radiopharmaceuticals

2) By Therapeutic: Alpha Emitters, Beta Emitters, Brachytherapy

Which Trends Are Contributing To Changes In The Radiopharmaceuticals Market?

Key companies operating within the radiopharmaceuticals market are increasingly entering into strategic collaborations to accelerate innovation and expand the reach of advanced diagnostic and therapeutic solutions. These joint ventures primarily focus on enhancing radiopharmaceutical development, bolstering regional production capacities, and supporting the increasing demand for precision imaging and targeted therapies. For example, in June 2023, the University of Pittsburgh Medical Center (UPMC), a US-based hospital system, joined forces with PharmaLogic Holdings Corporation to jointly develop and manufacture novel radiopharmaceuticals at a Pittsburgh facility. The partnership seeks to improve patient and clinician access to innovative diagnostic and therapeutic agents that are currently unavailable in neighboring regions. Through this non-exclusive agreement, UPMC and PharmaLogic will transform experimental radiopharmaceuticals into clinically practical medications, thereby supporting wider commercialization and speeding up the adoption of new nuclear medicine treatments.

Who Are The Firms Contributing To The Radiopharmaceuticals Market Ecosystem?

Major companies operating in the radiopharmaceuticals market are Cardinal Health, Curium Pharma, Siemens Healthineers AG, Novartis AG, General Electric Company (GE), IBA Group, Bayer AG, Lantheus Medical Imaging Inc., Bracco Imaging S.p.A., Eckert & Ziegler, Nihon Medi-Physics Co. Ltd., Fujifilm Corporation, ANSTO, Yantai Dongcheng Pharmaceutical Group Co. Ltd., Bracco Imaging SpA., Canon Inc., China Isotope & Radiation Corporation (CIRC), Alliance Medical, Advanced Accelerator Applications, JSC Isotope, Pharm-Sintez, Synektik SA, Polatom, RadioMedic sro, ÚJV Řež, Actinium Pharmaceuticals Inc., Alseres Pharmaceuticals Inc., Avid Radiopharmaceuticals, Fusion Pharmaceuticals, Peregrine Pharmaceuticals Inc., PETNET Solutions Inc., Positron Corporation, Triad Isotopes Inc., Telix Pharmaceuticals, Rosatom, Alliance Medical Group, Hologic Inc., Segami Corporation, Eczacýbaþý-Monrol Nuclear Products, NTP Radioisotopes.

Access The Complete Radiopharmaceuticals Market Report:

https://www.thebusinessresearchcompany.com/report/radiopharmaceutical-global-market-report

Which Regional Market Leads The Radiopharmaceuticals Market?

North America was the largest region in the global radiopharmaceuticals market in 2025. The Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the radiopharmaceuticals market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Radiopharmaceuticals Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=3471&type=smp

Browse Through More Reports Similar to the Global Radiopharmaceuticals Market 2026, By The Business Research Company

Radiotherapy Devices Market Report 2026

https://www.thebusinessresearchcompany.com/report/radiotherapy-devices-global-market-report

Cancer Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/cancer-diagnostics-global-market-report

Diagnostic Equipment Market Report 2026

https://www.thebusinessresearchcompany.com/report/diagnostic-equipment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795